Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05014477Unknown

Therapy Strategies After LAA Occluder Device Embolization

Role: lead

NCT04590898Completed

Peri-device Leakage Closure After LAAO

Role: lead

NCT04031274Unknown

Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry

Role: collaborator

NCT01834118Completed

Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension

Role: lead

All 4 trials loaded